1692 related articles for article (PubMed ID: 18948057)
1. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
2. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
Crawford Y; Ferrara N
Trends Pharmacol Sci; 2009 Dec; 30(12):624-30. PubMed ID: 19836845
[TBL] [Abstract][Full Text] [Related]
3. Pathways mediating VEGF-independent tumor angiogenesis.
Ferrara N
Cytokine Growth Factor Rev; 2010 Feb; 21(1):21-6. PubMed ID: 20005148
[TBL] [Abstract][Full Text] [Related]
4. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
Greenberg JI; Cheresh DA
Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
[TBL] [Abstract][Full Text] [Related]
5. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis.
Ferrara N
Curr Opin Hematol; 2010 May; 17(3):219-24. PubMed ID: 20308892
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy for cancer: an update.
Shojaei F; Ferrara N
Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
[TBL] [Abstract][Full Text] [Related]
8. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
9. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
10. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
11. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Loges S; Mazzone M; Hohensinner P; Carmeliet P
Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
14. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
15. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
16. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
17. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
18. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
Plavetić ND; Letilović T; Vrbanec D
Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
[TBL] [Abstract][Full Text] [Related]
19. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.
Shojaei F; Wu X; Malik AK; Zhong C; Baldwin ME; Schanz S; Fuh G; Gerber HP; Ferrara N
Nat Biotechnol; 2007 Aug; 25(8):911-20. PubMed ID: 17664940
[TBL] [Abstract][Full Text] [Related]
20. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
Sato Y
Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]